English  |  正體中文  |  简体中文  |  2826208  
???header.visitor??? :  31898401    ???header.onlineuser??? :  1509
???header.sponsordeclaration???
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
???ui.leftmenu.abouttair???

???ui.leftmenu.bartitle???

???index.news???

???ui.leftmenu.copyrighttitle???

???ui.leftmenu.link???

"yeh c g"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1??? ???jsp.browse.items-by-author.order2???

Showing items 1-6 of 6  (1 Page(s) Totally)
1 
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2021-08-31T06:42:20Z Phase i study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients Chang T.C.; Shiah H.S.; Yang C.H.; Yeh K.H.; ANN-LII CHENG; Shen B.N.; Wang Y.W.; Yeh C.G.; Chiang N.J.; Chang J.Y.; Chen L.T.
臺大學術典藏 2021-01-28T01:06:31Z Phase i study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients Chang T.C.; Shiah H.S.; Yang C.H.; KUN-HUEI YEH; Cheng A.L.; Shen B.N.; Wang Y.W.; Yeh C.G.; Chiang N.J.; Chang J.Y.; Chen L.T.
臺大學術典藏 2020-05-26T09:26:56Z Phase i study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients Chen L.T.;Chang J.Y;Chiang N.J;Yeh C.G;Wang Y.W;Shen B.N;Cheng A.L;Yeh K.H;Chih-Hsin Yang;Shiah H.S;Chang T.C; Chang T.C; Shiah H.S; CHIH-HSIN YANG; Yeh K.H; Cheng A.L; Shen B.N; Wang Y.W; Yeh C.G; Chiang N.J; Chang J.Y; Chen L.T.
國立成功大學 2015-03 Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients Chang, T. C.; Shiah, H. S.; Yang, C. H.; Yeh, K. H.; Cheng, A. L.; Shen, B. N.; Wang, Y. W.; Yeh, C. G.; Chiang, N. J.; Chang, J. Y.; Chen, L. T.
國立成功大學 2013-08-20 A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer Ko, A. H.; Tempero, M. A.; Shan, Y-S; Su, W-C; Lin, Y-L; Dito, E.; Ong, A.; Wang, Y-W; Yeh, C. G.; Chen, L-T
國立成功大學 2013-06 A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma Roy, A. C.; Park, S. R.; Cunningham, D.; Kang, Y. K.; Chao, Y.; Chen, L. T.; Rees, C.; Lim, H. Y.; Tabernero, J.; Ramos, F. J.; Kujundzic, M.; Cardic, M. B.; Yeh, C. G.; de Gramont, A.

Showing items 1-6 of 6  (1 Page(s) Totally)
1 
View [10|25|50] records per page